Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 0.15% & 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia
Status: Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 30 Dec 2019
Price : $35 *
At a glance
- Drugs SM 04554 (Primary)
- Indications Alopecia
- Focus Registrational; Therapeutic Use
- Sponsors Samumed
- 24 Dec 2019 Planned End Date changed from 1 Jun 2020 to 1 Jan 2021.
- 24 Dec 2019 Planned primary completion date changed from 1 Jun 2020 to 1 Jan 2021.
- 24 Dec 2019 Status changed from recruiting to active, no longer recruiting.